[HTML][HTML] Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: a randomized, double blind, active-and placebo-controlled, phase …
S Ishibashi, S Yamashita, H Arai, E Araki, K Yokote… - Atherosclerosis, 2016 - Elsevier
Background and aims To assess the efficacy and safety of K-877 (Pemafibrate), a novel
selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that possesses
unique PPARα activity and selectivity, compared with placebo and fenofibrate in
dyslipidaemic patients with high triglyceride (TG) and low high-density lipoprotein
cholesterol (HDL-C) levels. Methods and results This study was a double blind, placebo-
controlled, parallel-group 12-week clinical trial. The study randomized 224 patients to K-877 …
selective peroxisome proliferator-activated receptor α modulator (SPPARMα) that possesses
unique PPARα activity and selectivity, compared with placebo and fenofibrate in
dyslipidaemic patients with high triglyceride (TG) and low high-density lipoprotein
cholesterol (HDL-C) levels. Methods and results This study was a double blind, placebo-
controlled, parallel-group 12-week clinical trial. The study randomized 224 patients to K-877 …